Perioperative Intranasal Mupirocin for the Prevention of Surgical-Site Infections: Systematic Review of the Literature and Meta-Analysis
- 1 December 2005
- journal article
- research article
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 26 (12) , 916-922
- https://doi.org/10.1086/505453
Abstract
Objective: To review the evidence evaluating perioperative intranasal mupirocin for the prevention of surgical-site infections according to type of surgical procedure.Design: Systematic review and meta-analysis of published clinical trials.Setting: Studies included were either randomized clinical trial or prospective trials at a single institution that measured outcomes both before and after an institution-wide intervention (before-after trial). In all studies, intervention and control groups differed only by the use of perioperative intranasal mupirocin in the intervention group.Patients: Patients undergoing general or nongeneral surgery (eg, cardiothoracic surgery, orthopedic surgery, and neurosurgery).Main Outcome Measure: Risk of surgical-site infection following perioperative intranasal mupirocin versus usual care.Results: Three randomized and four before-after trials met the inclusion criteria. No reduction in surgical-site infection rate was seen in randomized general surgery trials (summary estimates: 8.4% in the mupirocin group and 8.1% in the control group; relative risk [RR], 1.04; 95% confidence interval [CI95], 0.81 to 1.33). In nongeneral surgery, the use of mupirocin was associated with a reduction in surgical-site infection in randomized trials (summary estimates: 6.0% in the mupirocin group and 7.6% in the control group; RR, 0.80; CI95, 0.58 to 1.10) and in before-after trials (summary estimates: 1.7% in the mupirocin group and 4.1% in the control group; RR, 0.40; CI95, 0.29 to 0.56).Conclusions: Perioperative intranasal mupirocin appears to decrease the incidence of surgical-site infection when used as prophylaxis in nongeneral surgery. Given its low risk and low cost, use of perioperative intranasal mupirocin should be considered in these settings.Keywords
This publication has 20 references indexed in Scilit:
- Treatment of Staphylococcus aureus Colonization and Prophylaxis for Infection with Topical Intranasal Mupirocin: An Evidence-Based ReviewClinical Infectious Diseases, 2003
- Current methods of the U.S. Preventive Services Task ForceAmerican Journal of Preventive Medicine, 2001
- Preventing Surgical Site Infections: A Surgeon's PerspectiveEmerging Infectious Diseases, 2001
- Guideline for Prevention of Surgical Site Infection, 1999Infection Control & Hospital Epidemiology, 1999
- The nose: an underestimated source of Staphylococcus aureus causing wound infectionJournal of Hospital Infection, 1998
- Reduction of Surgical-Site Infections in Cardiothoracic Surgery by Elimination of Nasal Carriage of Staphylococcus aureusInfection Control & Hospital Epidemiology, 1996
- Cost-Effectiveness of Perioperative Mupirocin Nasal Ointment in Cardiothoracic SurgeryInfection Control & Hospital Epidemiology, 1996
- The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infectionJournal of Hospital Infection, 1995
- A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnelJournal of Antimicrobial Chemotherapy, 1995
- CDC Definitions of Nosocomial Surgical Site Infections, 1992: A Modification of CDC Definitions of Surgical Wound InfectionsInfection Control & Hospital Epidemiology, 1992